Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Nelson

Obstetrics & Gynecology Dallas, TX Medical Doctor

NPI 1730382813 CMS profile 1295872

5201 Harry Hines Blvd, House Staff & Gme, Dallas, TX 75235

Open in the dashboard

General payments

$27,563

302 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$326,279 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Jeffrey Nelson of Dallas, TX is reported in the CMS Open Payments database as having received $27,563 across 302 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $326,279 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,290 46
2024 General $685 34
2023 General $3,506 37
2022 General $6,105 54
2021 General $6,234 51
2020 General $3,100 35
2019 General $3,643 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Nelson
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Jeffrey Nelson were reported at $4,290. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Jeffrey Nelson Obstetrics & Gynecology median Middle half National median
2019 $3,643 $172 $62–$391 $163
2020 $3,100 $94 $36–$222 $114
2021 $6,234 $136 $42–$369 $132
2022 $6,105 $160 $50–$433 $149
2023 $3,506 $169 $56–$423 $160
2024 $685 $152 $50–$371 $164
2025 $4,290 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $13,038 33 payments
  2. Aesculap, Inc. $5,901 13 payments
  3. Intuitive Surgical, Inc. $1,903 6 payments
  4. Merck Sharp & Dohme Corporation $1,514 11 payments
  5. SCYNEXIS, Inc. $1,174 4 payments
  6. AbbVie, Inc. $938 81 payments
  7. Sumitomo Pharma America, Inc. $595 32 payments
  8. Pfizer Inc. $307 14 payments
  9. Astellas Pharma US Inc $213 7 payments
  10. Millicent US Inc $175 10 payments
  11. Other $1,804 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,221 6 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $8,455 7 payments
  3. Food and Beverage $4,949 276 payments
  4. Education $1,646 5 payments
  5. Travel and Lodging $1,292 7 payments
  6. Consulting Fee $1,000 1 payment
Products named General payments · program years 2019–2025
  1. NEXPLANON Etonogestrel $8,851 26 payments
  2. CAIMAN VESSEL SEALERS $5,827 12 payments
  3. Nexplanon Womens Health $4,151 5 payments
  4. NEXPLANON Womens Health $1,514 11 payments
  5. DAVINCI XI $1,500 1 payment
  6. MYFEMBREE $516 28 payments
  7. ORILISSA $506 41 payments
  8. Da Vinci Surgical System $403 5 payments
  9. ORIAHNN $377 33 payments
  10. LO LOESTRIN FE $250 19 payments
  11. Other $3,333 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

95

Median for Obstetrics & Gynecology: 65

Drug cost

$8,812

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

36.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Imvexxy Estradiol Brand 11 $5,869
Estradiol Generic 49 $2,124
Estradiol (Once Weekly) Estradiol Brand 12 $617
Oxybutynin Chloride Er Oxybutynin Chloride Brand 12 $122
Escitalopram Oxalate Generic 11 $79

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$18,313

Medicare's payments for the services billed

Medicare patients

145

Average age 70

Services billed

341

145 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 51%
Diabetes 21%
Depression 21%
Ischemic heart disease 17%
Chronic kidney disease 17%
Osteoporosis 15%
Atrial fibrillation 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $231
$231 — —
INTRAROSA
  • MILLICENT US INC $90
$90 — —
Veozah
  • Astellas Pharma US Inc $59
$59 — —
ABRYSVO
  • PFIZER INC. $38
$38 — —
Wegovy
  • Novo Nordisk Inc $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

302 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record